➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Moodys
McKesson
Express Scripts
Harvard Business School

Last Updated: September 19, 2020

DrugPatentWatch Database Preview

CEPTAZ Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Ceptaz patents expire, and when can generic versions of Ceptaz launch?

Ceptaz is a drug marketed by Glaxosmithkline and is included in one NDA.

The generic ingredient in CEPTAZ is ceftazidime. There are seventeen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the ceftazidime profile page.

US ANDA Litigation and Generic Entry Outlook for Ceptaz

A generic version of CEPTAZ was approved as ceftazidime by ACS DOBFAR on November 20th, 1985.

  Start Trial

Summary for CEPTAZ
Drug patent expirations by year for CEPTAZ

US Patents and Regulatory Information for CEPTAZ

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline CEPTAZ ceftazidime INJECTABLE;INJECTION 050646-002 Sep 27, 1990 DISCN No No   Start Trial   Start Trial   Start Trial
Glaxosmithkline CEPTAZ ceftazidime INJECTABLE;INJECTION 050646-001 Sep 27, 1990 DISCN No No   Start Trial   Start Trial   Start Trial
Glaxosmithkline CEPTAZ ceftazidime INJECTABLE;INJECTION 050646-003 Sep 27, 1990 DISCN No No   Start Trial   Start Trial   Start Trial
Glaxosmithkline CEPTAZ ceftazidime INJECTABLE;INJECTION 050646-004 Sep 27, 1990 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Express Scripts
Medtronic
Johnson and Johnson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.